Shiva Malek highlights her work on cancer cell signaling and the importance of new spatial tools in understanding the bigger ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid ...

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...